1 / 6

A Guide On Using Meres100

A Guide On Using Meres100<br>

ovijain
Télécharger la présentation

A Guide On Using Meres100

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sirolimus Eluting BioResorbable Vascular Scaffold System Next Genera?on BioResorbable Scaffold. Low profile, 1.2 mm & deliverable system Optimal side branch access 100 µm Hybrid cell design gth, 2 en tr s l a i d a rh g i H 2 .3 0 Scaffold backbone PLLA 100 µm strut thickness¹ N o i t a ry r e t r a o t d l o f f a c s % 4 2 Closed cell Open cell 1 recoil, w o L .2 3% Low balloon overhang, short, abrupt balloon shoulders Drug coat of PDLLA + Sirolimus 1.25 µg/mm² Degradation over 3 years Couplets of tri-axial RO markers at either end² High vessel conformability² Size Matrix Diameters - 2.50, 2.75, 3.00, 3.25, 3.50, 4.00, 4.50 mm Lengths- 13, 16, 19, 24, 29, 32, 37, 40 mm

  2. N = 108, Prospec?ve, Non-Randomized, Mul?-Centre Study (16 Inves?ga?ng sites in India) Primary Demographics-Treatment Influencing Factors Diabe?cs (28%), Hypertensive (42%), Dyslipidemics (13%), Smokers (17%) Lesion characteris?cs- Lesion class A (7%), B1 (32%), B2 (56%), C (5%) Post Dilata?on 108 (100%)and Device Success 108 (100%) Clinical Endpoint at 1-Year* 6-Months f/up* 1-Year In-Hospital N = 108 (100%) 1-Month N = 108 (100%) 6-Months N = 108 (100%) ) N= 107 (99%) 0.2 1.0 0.75 Percentage (%) 0.15 ± 0.23 Binary Restenosis 0% 0.15 0.50 0.14 ± 0.22 Late Lumen Loss (mm) 0.25 0.0 0.10 –0.2 0.0 0.50 1.0 1.50 In-scaffold Late Lumen Loss at 6 months (mm) 0.07 ± 0.29 0.06 ± 0.15 0.05 0 In-Scaffold In-Segment Proximal Edge Distal Edge CTA 1-Year f/up 2 MLA: 7.41 mm Baseline 6-Months f/up 2 MLA: 7.36 mm OCT at 6-Months showed virtually complete strut coverage (99.3%) CTA at 1-Year showed low mean area stenosis of 11.33%

  3. 53 Years | Male | Diabe?c | Hypertensive | No family history | Non-smoker | Stable angina Diagnos?c Angio Final Result MeRes100 3.50 x 19 mm Baseline OCT 6-Months f/up 6-Months OCT f/up

  4. SCAFFOLD BACKBONE Scaffold Material Scaffold Strut Thickness Scaffold Diameters Scaffold Lengths : BioResorbable PLLA (Poly L-lactide) : 100 µm : 2.50, 2.75, 3.00, 3.25, 3.50, 4.00, 4.50 mm : 13, 16, 19, 24, 29, 32, 37, 40 mm SCAFFOLD RO MARKERS Tri-axial RO Markers TOP COAT-DRUG+POLYMER Drug Equivalent Drug Dose Polymer : Platinum (Couplets of tri-axial RO markers at either end, 120° apart from each other) : Sirolimus : 1.25 µg / mm : BioResorbable PDLLA (Poly D, L-lactide) 2 DELIVERY SYSTEM Delivery System Nominal Pressure (NP) Rated Burst Pressure (RBP) Balloon Overhang Shaft Outer Diameter Radiopaque Markers Usable Catheter Length Guide Catheter Compatibility Max. Guidewire : Rapid Exchange : 9 atm : 16 atm : < 0.5 mm : Proximal 1.95 F / Distal 2.7 F : 2 - Platinum / Iridium : 140 cm : 6 F (Min. I D 0.070" / 1.8 mm) : 0.014'’ (0.36 mm)

More Related